drugset / Trial / NCT01867957
Efficacy and Safety of Anthrax Vaccine, GC1109
Phase 1
Completed
20 enrolled
Seoul National University Hospital
Green Cross Corporation · collabLSK Global Pharma Services Co. Ltd. · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
1. BACKGROUND The newly developed anthrax vaccine GC1109 has been proven safe and effective in preclinical studies. 2. OBJECTIVE \- To evaluate the immunogenicity and safety of the anthrax vaccine GC1109 in healthy male volunteers. 3. STUDY DESIGN * single-blinded * randomized * placebo controlled * phase 1 study
Timeline
- Start
- 2009-02
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC1109 | Vaccine | 50 ug | Intramuscular |
| Subject | GC1109 | Vaccine | 100 ug | Intramuscular |